Back to search

Article

Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients

2021-05-15

Abstract excerpt

<h4>SUMMARY</h4> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are highly effective in healthy individuals. Patients with multiple myeloma (MM) are immunocompromised due to defects in humoral and cellular immunity as well as immunosuppressive therapies. The efficacy after two doses of SARS-CoV-2 mRNA vaccination in MM patients is currently unknown. Here, we report the case of a MM patient w...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a8188bdb-6181-57fd-b3e9-18287343a396
DOI
10.1101/2021.05.15.21256814
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patientsDOI 10.1101/2021.05.15.21256814
Cellular Mechanisms Associated with Sub-Optimal Immune Responses to SARS-CoV-2 Bivalent Booster Vaccination in Patients with Multiple MyelomaSemantic proximity
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patientsSemantic proximity
Loss of Anti-Spike Antibodies Following mRNA Vaccination for COVID-19 Among Patients with Multiple MyelomaSemantic proximity
Impact of Omicron variant on the response to SARS-CoV-2 mRNA Vaccination in multiple myelomaSemantic proximity
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myelomaSemantic proximity
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaSemantic proximity
SARS-CoV-2 Vaccines in Patients With Multiple MyelomaSemantic proximity
A phase I study of C-CAR088, a novel humanized anti-BCMA CAR T cell therapy in relapsed/refractory multiple myelomaSemantic proximity
Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.Semantic proximity
Rapid BCMA downmodulation on myeloma cells upon CAR T cell contact is mediated by trogocytosis and BCMA internalizationSemantic proximity
Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalizationSemantic proximity
COVID-19 Vaccine Failure in Chronic Lymphocytic Leukemia and Monoclonal B-Lymphocytosis; Humoral and Cellular ImmunitySemantic proximity
Select a neighboring publication to make it the new centre.